Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Award notice |
| Buyer: | Northern Health And Social Care Trust |
| Main Category: | Goods |
| Procurement Method: | Direct award |
| Method Rationale: | Purchase of drugs which are subject to patent protection/ Sole MA Holder, where no reasonable alternative or substitute exists. Section 41 schedule 5(5) of the PA2023 permits a direct award in the case of single supplier and permits the award if the following conditions are met in relations to the public contract - (a)due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and (b)there are no reasonable alternatives to those goods, services or works. |
| Tender Status: | Closed |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: |
All 3 notices for this procurement, oldest first.
Canakinumab
Canakinumab
Canakinumab
View Original Notice
Access the full notice on the official portal
🤝 Need a consortium or subcontracting partner?
SMEs & Primes team up to win opportunities like this. Find partners on the board.
Awarded to
| Award value: | £120,000 |
| Award status: | Pending |
The intended contract is for the supply of Canakinumab to Northern Health and Social Care Trust for up to a maximum of 3 years
Published contracts in the last 12 months
11
total contracts
—
total value
—
average contract size
Typical categories
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| 26 June 2025 |
| Application Deadline: | — |
| Contract Start Date: | — |
| Contract End Date: | — |
| Contract Duration: | NaN years |
| Procurement ID (OCID): | ocds-h6vhtk-0553ef |
| Notice Reference: | 035302-2025 |